ArticleJournal of diabetes2026
Urinary Liver-Type Fatty Acid-Binding Protein, Albuminuria, and eGFR Trajectories in Type 2 Diabetes.
Article in Journal of diabetes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundUrinary liver-type fatty acid-binding protein (L-FABP) reflects proximal tubular stress and has been proposed as a biomarker of diabetic kidney disease. We examined whether urinary L-FABP provides information on longitudinal kidney function beyond urinary albumin-to-creatinine ratio (UACR).
methodsThis retrospective cohort study included patients with type 2 diabetes who had UACR and urinary L-FABP measured simultaneously at the initial visit and underwent outpatient follow-up. The analysis included patients with at least three eGFR measurements over at least 2 years. eGFR trajectories were evaluated using linear mixed-effects models with random intercepts and slopes. UACR and L-FABP were analyzed as log(1 + x)-transformed continuous variables.
resultsThe analysis included 1,031 patients (age 58.1 years; 65.1% men), with a median follow-up of 4.76 years and a median of 10 eGFR measurements. Urinary L-FABP correlated with UACR (Spearman ρ = 0.526; p < 0.001). Both biomarkers were independently associated with lower baseline eGFR. In a model without UACR, higher L-FABP was associated with faster eGFR decline (-0.98 mL/min/1.73 m²/year per unit increase in log[1 + L-FABP]; p < 0.001). After adjustment for continuous UACR, the association was attenuated and no longer significant (-0.19; 95% CI, -0.49 to 0.11; p = 0.221), whereas UACR remained independently associated with eGFR decline. Results were unchanged after further adjustment for baseline eGFR and lipid parameters.
conclusionsUrinary L-FABP was associated with baseline kidney impairment but did not independently predict eGFR trajectory after continuous UACR was taken into account. Urinary L-FABP reflects kidney injury severity, although its incremental prognostic value beyond quantitatively assessed albuminuria was limited in this cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.